Osamu Tetsu, MD, PhD

TitleAssociate Professor
InstitutionUniversity of California San Francisco
Address1450 Third St
San Francisco CA 94158
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Chiba UniversityM.D.1989School of Medicine
    Chiba UniversityPh.D.1997Graduate School of Medicine
    Chiba UniversityResidency1997Department of Surgery
    University of California, San FranciscoPost-doc2002Cancer Research Institute

    Collapse Overview 
    Collapse Overview
    Osamu Tetsu, MD, PhD, is an Associate Professor and Director of the Head and Neck Cancer Research Laboratory in the Department of Otolaryngology – Head and Neck Surgery (OHNS) at the University of California, San Francisco. He received his MD from Chiba University, Japan and he completed his residency program from the Chiba University Hospital in Japan. Dr. Tetsu obtained his PhD in molecular immunology at Chiba University, and this was following by a postdoctoral in cancer biology at UCSF.

    Dr. Tetsu’s research focus is to understand the molecular mechanism of head and neck cancer, especially salivary gland tumors, and to identify novel therapeutic approaches to the treatment of various types of neoplasm in the head and neck. His laboratory is interested in molecular mechanism underlying initiation and progression of head and neck cancers and other malignancies. They have exploited the cell signaling pathways that make cancers different from normal tissues.

    Cancer Biology

    Tumor Initiation and Progression, Growth Control, Cell-Signaling, Targeted Therapy, and Molecular Biomarkers

    Professional Interests:
    Cancer Biology, Salivary gland and Head and Neck cancers, Targeted Therapy, Receptor Tyrosine Kinases (RTKs), cyclin D1, Cell-cycle Regulation, Signal Transduction, the Wnt/ß-Catenin Pathway, the Ras/MAPK Pathway, the Proteasome-Ubiquitin Pathway, Apoptotic Cell Death, Cellular Senescence, Developmental Therapeutics, Drug Discovery, Small-Molecule Inhibitors, and Molecular Biomarkers

    Education and Training:
    • Medical School: Chiba University, Japan
    • Residency: Chiba University Hospital, Japan – General and GI Surgery
    • PhD: Chiba University, Japan – Molecular Immunology
    • Postdoctoral: University of California, San Francisco – Cancer Biology

    Awards and Honors:
    • 1990 Chiba University Department of Surgery - Dr. Kaichi Isono, M.D. Award
    • 2000 Uehara Memorial Foundation – Uehara Scholar Award
    • 2003 American Cancer Society – Institutional Individual Award
    • 2004 Concern Foundation – Young Investigator Award
    • 2004 Chiba University School of Medicine Alumni Association - Outstanding Academic Achievement Award
    • 2005 V Foundation – V Scholar Award
    • 2010 American Head and Neck Society – Dr. Alando J Ballantyne, M.D. Research Award

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Tetsu O, McCormick F. ETS-targeted therapy: can it substitute for MEK inhibitors? Clin Transl Med. 2017 Dec; 6(1):16. PMID: 28474232.
      View in: PubMed
    2. Wang SJ, Asthana S, van Zante A, Heaton CM, Phuchareon J, Stein L, Higuchi S, Kishimoto T, Chiu CY, Olshen AB, McCormick F, Tetsu O. Establishment and characterization of an oral tongue squamous cell carcinoma cell line from a never-smoking patient. Oral Oncol. 2017 Jun; 69:1-10. PMID: 28559012.
      View in: PubMed
    3. Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F. Drug Resistance to EGFR Inhibitors in Lung Cancer. Chemotherapy. 2016; 61(5):223-35. PMID: 26910730; PMCID: PMC4844777 [Available on 02/25/17].
    4. Phuchareon J, McCormick F, Eisele DW, Tetsu O.. EGFR inhibition generates drug-tolerant persister cells by blocking AKT activity. Cancer Cell Microenviron. 2015; 2(3):e1045.
    5. Tetsu O, Phuchareon J, Eisele DW, Hangauer MJ, McCormick F. AKT inactivation causes persistent drug tolerance to EGFR inhibitors. Pharmacol Res. 2015 Dec; 102:132-7. PMID: 26453958.
      View in: PubMed
    6. Tetsu O, Phuchareon J, Eisele DW, McCormick F. ETS1 inactivation causes innate drug resistance to EGFR inhibitors. Mol Cell Oncol. 2016 Mar; 3(2):e1078924. PMID: 27308601; PMCID: PMC4905380.
    7. Phuchareon J, McCormick F, Eisele DW, Tetsu O. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc Natl Acad Sci U S A. 2015 Jul 21; 112(29):E3855-63. PMID: 26150526; PMCID: PMC4517222.
    8. You B, Yang YL, Xu Z, Dai Y, Liu S, Mao JH, Tetsu O, Li H, Jablons DM, You L. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. Oncotarget. 2015 Feb 28; 6(6):4357-68. PMID: 25738359; PMCID: PMC4414195.
    9. Tetsu O, Eisele DW, McCormick F. Resistance to EGFR-targeted therapy by Ets-1 inactivation. Cell Cycle. 2015; 14(20):3211-2. PMID: 26313421; PMCID: PMC4825599.
    10. Phuchareon J, Overdevest JB, McCormick F, Eisele DW, van Zante A, Tetsu O. Fatty Acid binding protein 7 is a molecular marker in adenoid cystic carcinoma of the salivary glands: implications for clinical significance. Transl Oncol. 2014 Dec; 7(6):780-7. PMID: 25500088; PMCID: PMC4311037.
    11. Phuchareon J, van Zante A, Overdevest JB, McCormick F, Eisele DW, Tetsu O. c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands. Transl Oncol. 2014 Oct; 7(5):537-45. PMID: 25389449; PMCID: PMC4225653.
    12. Heaton CM, Durr ML, Tetsu O, van Zante A, Wang SJ. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma. Laryngoscope. 2014 Jul; 124(7):E267-73. PMID: 24431303.
      View in: PubMed
    13. Ikeda Y, Oda K, Hiraike-Wada O, Koso T, Miyasaka A, Kashiyama T, Tanikawa M, Sone K, Nagasaka K, Maeda D, Kawana K, Nakagawa S, Fukayama M, Tetsu O, Fujii T, Yano T, Kozuma S. Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer. Oncol Rep. 2013 Aug; 30(2):584-8. PMID: 23733133.
      View in: PubMed
    14. Tetsu O, Phuchareon J, Chou A, Cox DP, Eisele DW, Jordan RC. Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Neoplasia. 2010 Sep; 12(9):708-17. PMID: 20824047; PMCID: PMC2933691.
    15. Phuchareon J, Ohta Y, Woo JM, Eisele DW, Tetsu O. Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. PLoS One. 2009 Jun 25; 4(6):e6040. PMID: 19557180; PMCID: PMC2698276.
    16. Senawong T, Phuchareon J, Ohara O, McCormick F, Rauen KA, Tetsu O. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet. 2008 Feb 01; 17(3):419-30. PMID: 17981815.
      View in: PubMed
    17. Okabe H, McCormick F, Tetsu O.. Modulation of MAPK-mediated phosphorylation and/or FBXW8-mediated ubiquitinylation of cyclin D1 in modulation of cellular proliferation. 2007.
    18. Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One. 2006 Dec 27; 1:e128. PMID: 17205132; PMCID: PMC1762433.
    19. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 2006 Mar 03; 311(5765):1287-90. PMID: 16439621.
      View in: PubMed
    20. Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F. Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol. 2005; 70:461-7. PMID: 16869784.
      View in: PubMed
    21. Tetsu O, Wakita K, McCormick F.Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products. 2004.
    22. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003 Mar; 3(3):233-45. PMID: 12676582.
      View in: PubMed
    23. Wakita K, McCormick F, Tetsu O. Method for screening ecdysone-inducible stable cell lines. Biotechniques. 2001 Aug; 31(2):414-8. PMID: 11515378.
      View in: PubMed
    24. Wakita K, Tetsu O, McCormick F. A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics. Cancer Res. 2001 Feb 01; 61(3):854-8. PMID: 11221869.
      View in: PubMed
    25. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999 Apr 01; 398(6726):422-6. PMID: 10201372.
      View in: PubMed
    26. Tetsu O, Ishihara H, Kanno R, Kamiyasu M, Inoue H, Tokuhisa T, Taniguchi M, Kanno M. mel-18 negatively regulates cell cycle progression upon B cell antigen receptor stimulation through a cascade leading to c-myc/cdc25. Immunity. 1998 Oct; 9(4):439-48. PMID: 9806630.
      View in: PubMed
    27. Hasegawa M, Tetsu O, Kanno R, Inoue H, Ishihara H, Kamiyasu M, Taniguchi M, Kanno M. Mammalian Polycomb group genes are categorized as a new type of early response gene induced by B-cell receptor cross-linking. Mol Immunol. 1998 Jun; 35(9):559-63. PMID: 9809583.
      View in: PubMed
    28. Kenmochi T, Asano T, Nakagori T, Kaneko K, Nakajima K, Tetsu O, Jingu K, Iwashita C, Kainuma O, Tokoro Y, Sugamoto Y, Sakamoto K, Hatakeyama E, Yamada K, Isono K. Successful gene transfer into murine pancreatic islets using polyamine transfection reagents. Transplant Proc. 1998 Mar; 30(2):470-2. PMID: 9532132.
      View in: PubMed
    29. Akasaka T, Tsuji K, Kawahira H, Kanno M, Harigaya K, Hu L, Ebihara Y, Nakahata T, Tetsu O, Taniguchi M, Koseki H. The role of mel-18, a mammalian Polycomb group gene, during IL-7-dependent proliferation of lymphocyte precursors. Immunity. 1997 Jul; 7(1):135-46. PMID: 9252126.
      View in: PubMed
    30. Tetsu O, Kanno R, Isono K, Taniguchi M, Kanno M. Cloning and characterization of two transcripts generated from the mel-13 gene positioned adjacent to the mammalian Polycomb group-related gene mel-18. Biochim Biophys Acta. 1996 Mar 01; 1305(3):109-12. PMID: 8597592.
      View in: PubMed
    31. Tetsu O, Sakamoto K, Uematsu T, Hachisu T, Tanaka H, Hishikawa E, Kashiwabara H, Yokoyama T.A case of liosarcoma on anterior chest wall. Japanese Journal of National Medical Services (IRYO). 1995; 49(7):568-571.
    32. Tetsu O, Furukawa H, Taniguchi T, Takahashi T, Hara T .A case of primary omental leiomyosarcoma. The Journal of the Japanese Practical Surgeon Society. 1993; 54(6):1648-1652.
    33. Furukawa H, Hara T, Taniguchi T, Tetsu O. A case of spontaneous intramural hematoma of the esophagus. Gastroenterol Jpn. 1993 Feb; 28(1):81-7. PMID: 8440426.
      View in: PubMed